-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$21.00201.72% Upside
Zevra Therapeutics, Inc. Frequently Asked Questions
-
What analysts cover Zevra Therapeutics, Inc.?
Zevra Therapeutics, Inc. has been rated by research analysts at Roth Capital, Maxim Group, JMP Securities, H.C. Wainwright, Canaccord Genuity in the past 90 days.